Hyperpigmentation of the skin
MONDO:001928931 clinical trials for this condition and its sub-types, 17 tagged with Hyperpigmentation of the skin itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hyperpigmentation of the skin
-
Legius syndrome 5 trials
-
Dowling-Degos disease 0 trials · 4 incl. sub-types
4 sub-types
- Dowling-Degos disease 1 4 trials
- Dowling-Degos disease 2 0 trials
- Dowling-Degos disease 4 0 trials
- Dowling-degos disease 3 0 trials
-
Schwannomatosis 3 trials
4 sub-types
- 22q-related schwannomatosis 0 trials
- LZTR1-related schwannomatosis 0 trials
- SMARCB1-related schwannomatosis 0 trials
- Neurofibromatosis, type III, mixed central and peripheral 0 trials
-
3 sub-types
-
H syndrome 0 trials
-
Acromelanosis 0 trials
-
Cafe au lait spots, multiple 0 trials
-
Dermatopathia pigmentosa reticularis 0 trials
-
Familial generalized lentiginosis 0 trials
-
1 sub-type
-
Gastrocutaneous syndrome 0 trials
-
Mosaic Legius syndrome 0 trials
-
Phakomatosis pigmentovascularis 0 trials
3 sub-types
- Phakomatosis cesioflammea 0 trials
- Phakomatosis cesiomarmorata 0 trials
- Phakomatosis spilorosea 0 trials
Most studied deeper sub-types
-
Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
Disease control CancelledThis phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control ApprovedThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC